Ensign Peak Advisors
KNTE

Ensign Peak Advisors’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Ensign Peak Advisors’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,263
Closed -$59K – 2219
2022
Q1 		$59K Sell
5,263
-9,737
-65% -$107K ﹤0.01% 2106
2021
Q4 		$266K Hold
15,000
– – ﹤0.01% 1854
2021
Q3 		$345K Hold
15,000
– – ﹤0.01% 1693
2021
Q2 		$349K Hold
15,000
– – ﹤0.01% 1651
2021
Q1 		$467K Hold
15,000
– – ﹤0.01% 1603
2020
Q4 		$597K Buy
+15,000
New +$602K ﹤0.01% 1563

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ensign Peak Advisors's KNTE Position: Q2 2022 in Review

Ensign Peak Advisors sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2022, closing a stake of 5,263 shares — an estimated $59K sold.

Ensign Peak Advisors first reported a position in KNTE in Q4 2020 and held it in 6 quarters. The position peaked at $597K in Q4 2020. 73 funds tracked by Wall St. Rank hold KNTE as of Q2 2022.

  • Ensign Peak Advisors reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 5,263 Kinnate Biopharma Inc. Common Stock shares in Q2 2022, an estimated $59K.
  • Ensign Peak Advisors first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 6 quarters.
  • Ensign Peak Advisors's Kinnate Biopharma Inc. Common Stock position peaked at $597K in Q4 2020.
  • 73 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2022.

Based on Ensign Peak Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.